Strategy-making Process and Firm Performance in Iranian Pharmaceutical Industry.

Seyyed Abolfazl Abolfazli, Mehdi Mohammadzadeh, Farzad Peiravian, Jafar Zonoozi, Hesam Sharifnia, Ali Vasheghani

Abstract read

In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Seyyed Abolfazl AbolfazliDepartment of Pharmacoeconomics and Pharmacy Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mehdi MohammadzadehDepartment of Pharmacoeconomics and Pharmacy Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Farzad PeiravianDepartment of Pharmacoeconomics and Pharmacy Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Jafar ZonooziDepartment of Pharmacoeconomics and Pharmacy Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hesam SharifniaDepartment of Business Management, Faculty of Economic and Management, Urmia University, Urmia, Iran.

Ali VasheghaniDepartment of Pharmacoeconomics and Pharmacy Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the relationship between main dimensions in the strategy-making process, environmental complexity, and performance in pharmaceutical companies of Iran. Results argue that pharmaceutical companies like other industries place differing emphasis on strategy-making and employ different modes of strategy-making. It offers a typology of different modes of strategy-making that most likely exist in pharmaceutical companies and hypothesizes how this typology relates to performance. It then describes the results of an empirical study of the strategy-making processes of pharmaceutical companies. The structural equation analysis of the data from 31 pharmaceutical companies indicates that there are simplistic, adaptive, entrepreneurial, participative, and SPACE (Strategy making Process According to Complexity Environment) modes of strategy-making in pharmaceutical companies; of these modes, SPACE mode exhibited a significant relationship with performance.

Indexed as

Partial least square structural equation modelingPharmaceutical companiesSmart PLSSPACE modeStrategy-making

Identifiers

PMID31089387

PMCPMC6487417

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.